A hunger-drug trial stopped early; exploratory scores fell modestly, then neared baseline after treatment ended.
Aardvark Therapeutics (AARD) halted its Phase 3 HERO trial early, reporting exploratory data showing modest reductions in HQ-CT scores for ARD-101, a hunger-suppressing drug for Prader-Willi syndrome (PWS). Scores rebounded near baseline post-treatment. The FDA lifted its clinical hold, and Aardvark plans to meet with the FDA to design a new Phase 3 trial, aiming to resume PWS clinical activities in 2027. ARD-101 was generally well-tolerated, with mild to moderate adverse events.
How this was made
The 30-second read
Why it matters
The early termination and modest efficacy data introduce uncertainty about the path to approval, likely prompting short‑term sell pressure. However, the FDA’s lift of the clinical hold and plans for a new Phase 3 design could mitigate long‑term concerns.
Market read
Primary disclosure of early‑stage trial data for a micro‑cap biotech; relevance is high for specialty investors but limited for broader market.
What to watch
Potential for ARD-101 to be repositioned for metabolic diseases beyond PWS, and the lifted clinical hold may be viewed positively.
Background
Aardvark Therapeutics (Nasdaq: AARD) focuses on small‑molecule hunger‑suppression drugs for Prader‑Willi syndrome. The HERO Phase 3 trial was stopped early after enrolling 67 of 90 participants.
Ticker impact
Aardvark Therapeutics disclosed early termination of its Phase 3 HERO trial and exploratory efficacy data for ARD-101.
likely pressure as market prices in limited efficacy and trial uncertainty
The data are primary, first‑report clinical results for a micro‑cap biotech; investors typically react negatively to early terminations and modest outcomes.
Market effects
May dampen sentiment in the rare‑disease biotech space and affect peers developing hunger‑suppression therapies.
Limited to U.S. biotech investors; no broader regional effect.
Low global relevance beyond niche biotech investors.
Counterpoint
If the FDA meeting leads to a revised trial design with lower dosing, the long‑term upside could remain, making the dip a buying opportunity.
Key entities
- CompanyAardvark Therapeutics, Inc.
Clinical‑stage biotech developing ARD-101 for hyperphagia in PWS.
- RegulatorFDA
Lifted the clinical hold on ARD-101 and will meet with Aardvark to discuss trial design.
